ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer
Journal of Molecular Pathology · 04.06.2026 · 7 (2) · 22
DOI: 10.3390/jmp7020022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Pathology, online erschienen am 04.06.2026. Verfasst von Roger Ferreira und 6 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Ataxia telangiectasia-mutated kinase is encoded by the ATM gene. This gene is altered in many cancer types; however, it is most relevant for eligibility of poly-ADP-ribose polymerase inhibitor (PARPi) therapy in metastatic castrate-resistant prostate cancer in Canada. Non-benign ATM alterations are relatively uncommon, seen in less than 10% of prostate cancers; however, many of these are variants of uncertain significance with limited evidence of clinical significance or actionability.
Methods
To aid in variant classification of next-generation sequencing results, ATM immunohistochemistry (IHC) is performed on patient tumour samples to serve as patient-specific functional evidence for ATM protein loss.
Results
ATM IHC demonstrates strong concordance with known loss-of-function variants and copy number losses. Additionally, it can be used to clarify ATM protein loss in cases involving variants of uncertain significance (VUSs) or copy number deletions.
Conclusions
Incorporation of ATM IHC into clinical testing for prostate cancer represents a relatively cost-effective orthogonal approach that can rescue poor-quality NGS results and clarify the functional impact of ATM VUSs on protein expression. Overall, this strategy may provide useful supportive evidence in prostate cancer biomarker testing and interpretation.
Zitieren
APA
Ferreira, R., Bisson, K. R., Beharry, A., Nicholas, C., Iafolla, M., Bidnur, S., & Sheffield, B. S. (2026). ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer. Journal of Molecular Pathology, 7(2), 22. https://doi.org/10.3390/jmp7020022
Vancouver
Ferreira R, Bisson KR, Beharry A, Nicholas C, Iafolla M, Bidnur S, et al. ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer. Journal of Molecular Pathology. 2026;7(2):22. doi:10.3390/jmp7020022
BibTeX
@article{Ferreira2026,
author = {Ferreira, Roger and Bisson, Kassandra R. and Beharry, Andrea and Nicholas, Champica and Iafolla, Marco and Bidnur, Samir and Sheffield, Brandon S.},
title = {ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer},
journal = {Journal of Molecular Pathology},
year = {2026},
volume = {7},
number = {2},
pages = {22},
doi = {10.3390/jmp7020022}
}
EUVIMED